Vaccines

Trial phase

(1   2   3)

Prior vaccine development experience

Approval status

Pre-orders

(Later, -, Soon)

Immune response

Astrazeneca-Oxford

1   2   3

No

Review

Soon

70%*

Cansino biologics

1   2   3

Yes

Limited

Soon

High

Gamaleya research institute

1   2   3

Yes

Limited

Soon

Moderate

Inovio-cepi

1   2   3

No

-

Later

Not reported

Johnson & Johnson Barda Janssen

1   2   3

Yes

-

Later

Moderate

Moderna-Niaid

1   2   3

No

Review

Soon

94.5%

Novavax

1   2   3

No

-

-

High

Pfizer-Biontech

1   2   3

No

Review

Soon

95%

Sinopharm-Beijing institute of biological products

1   2   3

Yes

Limited

-

Moderate

Sinovac-instituto Butantan

1   2   3

No

-

-

Low